[REVISION HISTORY]
FDA panel recommends benefits of Grail Galleri test
Updated 1 time since CLSTR started tracking revisions of this situation.
What changed
2026-09-23 20:21 UTC → 2026-09-24 01:52 UTC ·
added
removed
FDA review panel recommends benefits of GRAIL Grail Galleri cancer blood test
GRAIL, Inc. is undergoing a regulatory review by an FDA advisory panel regarding its Galleri multi-cancer early detection blood test. The test, intended for adults aged 50 and older, identifies DNA fragments shed by tumor cells to detect multiple types of cancer. While FDA reviewers have reported no major outstanding concerns regarding primary safety analysis, they have tasked the Molecular and Clinical Genetics Panel with evaluating whether clinical performance data justifies the company’s proposed labeling for ‘early’ cancer detection. The panel must determine if the test’s benefits outweigh risks such as missed diagnoses or false alarms. Data from the PATHFINDER 2 study indicated a specificity of 99.64% and a positive predictive value of 60.3%. Among those with newly diagnosed primary cancers, 53% were in stage 1 or 2, and the test correctly predicted the cancer’s likely origin in 91.3% of cases. Currently, On September 23, 2026, the FDA’s Molecular and Clinical Genetics Devices Committee issued a recommendation stating that the benefits of the Galleri test is available outweigh its risks for the target population. The committee voted 7-2, with one abstention, in favor of the United States via out-of-pocket payments, often exceeding $700. Formal FDA approval test’s benefit-risk profile. While the panel reached a unanimous decision regarding safety, votes on the test’s effectiveness were more divided, resulting in a 6-4 split. Although the panel’s recommendation is viewed as nonbinding, it marks a critical step that significant milestone toward potential FDA approval. Such approval could facilitate coverage through Medicare and private insurers, significantly increasing accessibility. moving the test beyond its current status of being primarily available via out-of-pocket payments. Medical experts noted that while the technology is promising, further research is required to address concerns regarding false positives and the clinical value of investigating detected signals.
Versions
- 2026-09-24 01:52 UTC FDA panel recommends benefits of Grail Galleri test
- 2026-09-23 20:21 UTC FDA review of GRAIL Galleri cancer blood test
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.